Core Alzheimer's Disease (AD) biomarkers are the cerebrospinal fluid (CSF) proteins amyloid beta 42 and beta 40, and the tau proteins, total and phosphorylated. Their use is recommended by research guidelines for diagnostic purpose and for stratification of patients for clinical trials. However, novel potential biomarkers are needed, which can mirror risk factors and other different mechanisms of the disease, hopefully in less invasive biological fluids or matrices. Studies on blood, urine, saliva, tears gave promising results, and several novel molecules have been identified, as potential brain derived biomarkers, thanks to the development of novel ultrasensitive technologies. In this review, we discuss about advantages and limits of the classical CSF biomarkers of AD, as well as of novel CSF candidate biomarkers and recent promises from alternative matrices.

Sancesario, G., Bernardini, S. (2019). AD biomarker discovery in CSF and in alternative matrices. CLINICAL BIOCHEMISTRY, 72, 52-57 [10.1016/j.clinbiochem.2019.08.008].

AD biomarker discovery in CSF and in alternative matrices

Sancesario G.;Bernardini S.
2019-01-01

Abstract

Core Alzheimer's Disease (AD) biomarkers are the cerebrospinal fluid (CSF) proteins amyloid beta 42 and beta 40, and the tau proteins, total and phosphorylated. Their use is recommended by research guidelines for diagnostic purpose and for stratification of patients for clinical trials. However, novel potential biomarkers are needed, which can mirror risk factors and other different mechanisms of the disease, hopefully in less invasive biological fluids or matrices. Studies on blood, urine, saliva, tears gave promising results, and several novel molecules have been identified, as potential brain derived biomarkers, thanks to the development of novel ultrasensitive technologies. In this review, we discuss about advantages and limits of the classical CSF biomarkers of AD, as well as of novel CSF candidate biomarkers and recent promises from alternative matrices.
2019
Pubblicato
Rilevanza internazionale
Recensione
Comitato scientifico
Settore BIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA
English
Alzheimer Disease; Biomarkers; Humans; Proteins
Sancesario, G., Bernardini, S. (2019). AD biomarker discovery in CSF and in alternative matrices. CLINICAL BIOCHEMISTRY, 72, 52-57 [10.1016/j.clinbiochem.2019.08.008].
Sancesario, G; Bernardini, S
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0009912019304175-main.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 1.92 MB
Formato Adobe PDF
1.92 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/237775
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact